NorthStar Trial Analysis at ELCC 2026: Local Consolidative Therapy in EGFR-Mutant NSCLC

oncodaily - The management of metastatic EGFR-mutant non-small cell lung cancer (NSCLC) has been transformed by the introduction of third-generation EGFR tyrosine kinase inhibitors, particularly osimertinib. While systemic therapy achieves meaningful disease […]

AI Summary: ELCC 2026 brought together clinicians and investigators to present pivotal lung‑cancer studies, including localized consolidative therapy, SBRT sequencing with immunotherapy, and trials addressing under‑represented KRAS and EGFR populations. The conference highlighted survival and tumor‑control signals, networked international collaborators, and emphasized real‑world applicability — proving once again that conferences are where hope meets peer review.


At ELCC: late‑breaking trials reshaping clinical practice

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily


OTHER: misc lung oncology studies, regulatory and surgical updates

3 months / medicalxpress

3 months / oncodaily

3 months / nature

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / medicalxpress


Precision push: molecular testing, KRAS degraders, ADC collaborations advancing care

3 months / oncodaily

3 months / medicalxpress

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily


Voices from ELCC: clinicians share breakthroughs and practical takeaways

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily


All Other Stories

3 months / oncodaily

3 months / oncodaily

3 months / nature

3 months / medicalxpress

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / medicalxpress

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily





Related Stories


Phase I lung cancer trials consolidating at top-performing U.S. sites / 2 months

Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 7 days

Teclistamab shows survival benefit prompting earlier use discussions / 21 days

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 2 months

Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 2 months

Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 2 months

Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 3 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Obesity, Wildlife, Pancreatic Cancer, Infectious Disease and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.